flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants 🚨 Journal Club: FLOW Trial

To address this question, we performed an integrated time-resolved analysis of the renal transcriptome and proteome in parallel with the renal and plasma metabolomes in control mice and mice with an induced deletion of Bmal1 in the renal tubule

B12 is essential for converting food into energy, particularly through the metabolism of carbohydrates and fats

J., Greenhaff, P

Always inform your GP or pharmacist before starting any new supplements, as interactions with other medications should be considered

Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al.)

10.1038/s41586-023-05739-9 70 SeibtT